TrialBone marrow transplantation2019

A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma.

Noa Biran et al.PubMed ↗Publisher ↗

No numbers read from the abstract.